retatrutide nonalcoholic steatohepatitis trial Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment retatrutide nonalcoholic fatty liver disease

These include improvements in blood glucose control, reductions in blood pressure, and better overall metabolic function

The 24.2% weight reduction at 48 weeks, combined with improvements in triglycerides, liver enzymes, and insulin sensitivity markers, positions Retatrutide as the more mechanistically complete compound in the Retatrutide vs Tirzepatide framework, pending Phase 3 confirmation

JAMA 2007;298:2038e47

NIDDK Emerging Therapies and Oral GLP-1 Options Eli Lillys development of orforglipron, an oral GLP-1 receptor agonist, marks a significant advancement in diabetes treatment

Shifts in hormones, metabolism, and body composition can make this transition especially difficult for weight management

Recommendations for total fluid intake include not just water, but all foods and beverages